Dopaminergic Inhibition of Catecholamine Secretion from Chromaffin Cells: Evidence that Inhibition Is Mediated by D4 and D5 Dopamine Receptors

: Previous studies have suggested that activation of D2‐like dopamine receptors inhibits catecholamine secretion from adrenal chromaffin cells. The purpose of this study was to determine whether the activation of D1‐like receptors on chromaffin cells affects either catecholamine release from the cel...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neurochemistry 1996-01, Vol.66 (1), p.222-232
Hauptverfasser: Dahmer, Mary K., Senogles, Susan E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 232
container_issue 1
container_start_page 222
container_title Journal of neurochemistry
container_volume 66
creator Dahmer, Mary K.
Senogles, Susan E.
description : Previous studies have suggested that activation of D2‐like dopamine receptors inhibits catecholamine secretion from adrenal chromaffin cells. The purpose of this study was to determine whether the activation of D1‐like receptors on chromaffin cells affects either catecholamine release from the cells or the inhibition of secretion by D2‐like dopamine receptors. Both D1‐ and D2‐selective agonists inhibited secretion elicited by dimethylphenylpiperazinium (DMPP), veratridine, and high K+ levels. The D1‐selective agonists 6‐chloro‐7,8‐dihydroxy‐3‐allyl‐1‐phenyl‐2,3,4,5‐tetrahydro‐1H‐3‐benzazepine (Cl‐APB) and SKF‐38393 inhibited DMPP‐stimulated catecholamine secretion in a concentration‐dependent manner; 50% inhibition was obtained with ∼10 µM Cl‐APB and ∼100 µM SKF‐38393. Of the D2‐selective agonists, bromocriptine was a more potent inhibitor of DMPP‐stimulated catecholamine release than was quinpirole. The inhibition of secretion caused by Cl‐APB or SKF‐38393 was additive with the inhibition caused by bromocriptine. Pertussis toxin treatment (50 ng/ml, 18 h) attenuated the inhibitory effect of D2‐selective, but not D1‐selective, dopamine agonists. In addition, forskolin‐stimulated adenylyl cyclase activity was inhibited by D2‐selective, but not D1‐selective, agonists. Neither D1‐ nor D2‐selective agonists stimulated adenylyl cyclase activity in the cells, although cyclase activity was stimulated by forskolin, carbachol, and vasoactive intestinal peptide. DMPP‐stimulated Ca2+ uptake was inhibited by both D1‐ and D2‐selective dopamine agonists. PCR analysis was used to determine which of the dopamine receptor subtypes within the D1‐like and D2‐like subfamilies was responsible for the observed inhibition. PCR analysis indicated that mRNA for only D4 and D5 dopamine receptor subtypes was present in chromaffin cells. These combined data suggest that D1‐ and D2‐selective agonists inhibit Ca2+ uptake and catecholamine secretion by activating D4 and D5 dopamine receptors on chromaffin cells.
doi_str_mv 10.1046/j.1471-4159.1996.66010222.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77924849</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17023992</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4402-23a1065cc046ec6f95fece0bed05d38318a0784199140908c58f34c6d288087c3</originalsourceid><addsrcrecordid>eNqVkV2PEyEUhonRrHX1J5iQaLyb8cAAA3plputas2rixzWhDFia-agw1e2f8DdLtx_xzpgQSM778h44D0LPCJQEmHi5LgmrScEIVyVRSpRCAAFKaXl7D83O2n00g1wtKmD0IXqU0hqACCbIBbqQnFLF5Qz9no8b04fBxe_B4sWwCsswhXHAo8eNmZxdjd2djr84G92d5OPY42aVd-N9GHDjui69wlc_Q-sG6_C0MtPfUYuEP7g25LQWL3d4zrAZWjzn-NQbf3bWbaYxpsfogTddck-O5yX69vbqa_OuuPl0vWje3BSWMaAFrQwBwa3N43BWeMV9ToCla4G3layINFBLlodDGCiQlktfMStaKiXI2laX6MUhdxPHH1uXJt2HZPM_zODGbdJ1rSiTTP3TSGqglVI0G18fjDaOKUXn9SaG3sSdJqD32PRa79HoPRq9x6ZP2PRtvv302Ga77F17vnvklPXnR90kazofzWBDOtuoEpTXJNuuD7ZfoXO7_3mBfv-xyetUqP4AKPG1KA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17023992</pqid></control><display><type>article</type><title>Dopaminergic Inhibition of Catecholamine Secretion from Chromaffin Cells: Evidence that Inhibition Is Mediated by D4 and D5 Dopamine Receptors</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Dahmer, Mary K. ; Senogles, Susan E.</creator><creatorcontrib>Dahmer, Mary K. ; Senogles, Susan E.</creatorcontrib><description>: Previous studies have suggested that activation of D2‐like dopamine receptors inhibits catecholamine secretion from adrenal chromaffin cells. The purpose of this study was to determine whether the activation of D1‐like receptors on chromaffin cells affects either catecholamine release from the cells or the inhibition of secretion by D2‐like dopamine receptors. Both D1‐ and D2‐selective agonists inhibited secretion elicited by dimethylphenylpiperazinium (DMPP), veratridine, and high K+ levels. The D1‐selective agonists 6‐chloro‐7,8‐dihydroxy‐3‐allyl‐1‐phenyl‐2,3,4,5‐tetrahydro‐1H‐3‐benzazepine (Cl‐APB) and SKF‐38393 inhibited DMPP‐stimulated catecholamine secretion in a concentration‐dependent manner; 50% inhibition was obtained with ∼10 µM Cl‐APB and ∼100 µM SKF‐38393. Of the D2‐selective agonists, bromocriptine was a more potent inhibitor of DMPP‐stimulated catecholamine release than was quinpirole. The inhibition of secretion caused by Cl‐APB or SKF‐38393 was additive with the inhibition caused by bromocriptine. Pertussis toxin treatment (50 ng/ml, 18 h) attenuated the inhibitory effect of D2‐selective, but not D1‐selective, dopamine agonists. In addition, forskolin‐stimulated adenylyl cyclase activity was inhibited by D2‐selective, but not D1‐selective, agonists. Neither D1‐ nor D2‐selective agonists stimulated adenylyl cyclase activity in the cells, although cyclase activity was stimulated by forskolin, carbachol, and vasoactive intestinal peptide. DMPP‐stimulated Ca2+ uptake was inhibited by both D1‐ and D2‐selective dopamine agonists. PCR analysis was used to determine which of the dopamine receptor subtypes within the D1‐like and D2‐like subfamilies was responsible for the observed inhibition. PCR analysis indicated that mRNA for only D4 and D5 dopamine receptor subtypes was present in chromaffin cells. These combined data suggest that D1‐ and D2‐selective agonists inhibit Ca2+ uptake and catecholamine secretion by activating D4 and D5 dopamine receptors on chromaffin cells.</description><identifier>ISSN: 0022-3042</identifier><identifier>EISSN: 1471-4159</identifier><identifier>DOI: 10.1046/j.1471-4159.1996.66010222.x</identifier><identifier>PMID: 8522958</identifier><identifier>CODEN: JONRA9</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - pharmacology ; Adenylate Cyclase Toxin ; Adenylyl cyclase ; Adenylyl Cyclases - metabolism ; Adrenal gland ; Adrenal Medulla - drug effects ; Adrenal Medulla - metabolism ; Adrenals. Interrenals ; Adrenomedullary hormones. Regulation ; Animals ; Base Sequence ; Benzazepines - pharmacology ; Biological and medical sciences ; Bromocriptine - pharmacology ; Ca2+ uptake ; Calcium - physiology ; Catecholamines - metabolism ; Cattle ; Cells, Cultured ; Colforsin - pharmacology ; Cyclic AMP - physiology ; Depression, Chemical ; Dimethylphenylpiperazinium Iodide - antagonists &amp; inhibitors ; Dopamine - physiology ; Dopamine Agonists - pharmacology ; Fundamental and applied biological sciences. Psychology ; Molecular Sequence Data ; PCR ; Pertussis Toxin ; Polymerase Chain Reaction ; Potassium - antagonists &amp; inhibitors ; Receptors, Dopamine - drug effects ; Receptors, Dopamine - genetics ; Receptors, Dopamine - physiology ; Receptors, Dopamine D1 - physiology ; Receptors, Dopamine D2 - physiology ; Receptors, Dopamine D4 ; Receptors, Dopamine D5 ; Second Messenger Systems - drug effects ; Veratridine - antagonists &amp; inhibitors ; Vertebrates: endocrinology ; Virulence Factors, Bordetella - pharmacology</subject><ispartof>Journal of neurochemistry, 1996-01, Vol.66 (1), p.222-232</ispartof><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4402-23a1065cc046ec6f95fece0bed05d38318a0784199140908c58f34c6d288087c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1471-4159.1996.66010222.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1471-4159.1996.66010222.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,4024,27923,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2962571$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8522958$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dahmer, Mary K.</creatorcontrib><creatorcontrib>Senogles, Susan E.</creatorcontrib><title>Dopaminergic Inhibition of Catecholamine Secretion from Chromaffin Cells: Evidence that Inhibition Is Mediated by D4 and D5 Dopamine Receptors</title><title>Journal of neurochemistry</title><addtitle>J Neurochem</addtitle><description>: Previous studies have suggested that activation of D2‐like dopamine receptors inhibits catecholamine secretion from adrenal chromaffin cells. The purpose of this study was to determine whether the activation of D1‐like receptors on chromaffin cells affects either catecholamine release from the cells or the inhibition of secretion by D2‐like dopamine receptors. Both D1‐ and D2‐selective agonists inhibited secretion elicited by dimethylphenylpiperazinium (DMPP), veratridine, and high K+ levels. The D1‐selective agonists 6‐chloro‐7,8‐dihydroxy‐3‐allyl‐1‐phenyl‐2,3,4,5‐tetrahydro‐1H‐3‐benzazepine (Cl‐APB) and SKF‐38393 inhibited DMPP‐stimulated catecholamine secretion in a concentration‐dependent manner; 50% inhibition was obtained with ∼10 µM Cl‐APB and ∼100 µM SKF‐38393. Of the D2‐selective agonists, bromocriptine was a more potent inhibitor of DMPP‐stimulated catecholamine release than was quinpirole. The inhibition of secretion caused by Cl‐APB or SKF‐38393 was additive with the inhibition caused by bromocriptine. Pertussis toxin treatment (50 ng/ml, 18 h) attenuated the inhibitory effect of D2‐selective, but not D1‐selective, dopamine agonists. In addition, forskolin‐stimulated adenylyl cyclase activity was inhibited by D2‐selective, but not D1‐selective, agonists. Neither D1‐ nor D2‐selective agonists stimulated adenylyl cyclase activity in the cells, although cyclase activity was stimulated by forskolin, carbachol, and vasoactive intestinal peptide. DMPP‐stimulated Ca2+ uptake was inhibited by both D1‐ and D2‐selective dopamine agonists. PCR analysis was used to determine which of the dopamine receptor subtypes within the D1‐like and D2‐like subfamilies was responsible for the observed inhibition. PCR analysis indicated that mRNA for only D4 and D5 dopamine receptor subtypes was present in chromaffin cells. These combined data suggest that D1‐ and D2‐selective agonists inhibit Ca2+ uptake and catecholamine secretion by activating D4 and D5 dopamine receptors on chromaffin cells.</description><subject>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - pharmacology</subject><subject>Adenylate Cyclase Toxin</subject><subject>Adenylyl cyclase</subject><subject>Adenylyl Cyclases - metabolism</subject><subject>Adrenal gland</subject><subject>Adrenal Medulla - drug effects</subject><subject>Adrenal Medulla - metabolism</subject><subject>Adrenals. Interrenals</subject><subject>Adrenomedullary hormones. Regulation</subject><subject>Animals</subject><subject>Base Sequence</subject><subject>Benzazepines - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Bromocriptine - pharmacology</subject><subject>Ca2+ uptake</subject><subject>Calcium - physiology</subject><subject>Catecholamines - metabolism</subject><subject>Cattle</subject><subject>Cells, Cultured</subject><subject>Colforsin - pharmacology</subject><subject>Cyclic AMP - physiology</subject><subject>Depression, Chemical</subject><subject>Dimethylphenylpiperazinium Iodide - antagonists &amp; inhibitors</subject><subject>Dopamine - physiology</subject><subject>Dopamine Agonists - pharmacology</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Molecular Sequence Data</subject><subject>PCR</subject><subject>Pertussis Toxin</subject><subject>Polymerase Chain Reaction</subject><subject>Potassium - antagonists &amp; inhibitors</subject><subject>Receptors, Dopamine - drug effects</subject><subject>Receptors, Dopamine - genetics</subject><subject>Receptors, Dopamine - physiology</subject><subject>Receptors, Dopamine D1 - physiology</subject><subject>Receptors, Dopamine D2 - physiology</subject><subject>Receptors, Dopamine D4</subject><subject>Receptors, Dopamine D5</subject><subject>Second Messenger Systems - drug effects</subject><subject>Veratridine - antagonists &amp; inhibitors</subject><subject>Vertebrates: endocrinology</subject><subject>Virulence Factors, Bordetella - pharmacology</subject><issn>0022-3042</issn><issn>1471-4159</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkV2PEyEUhonRrHX1J5iQaLyb8cAAA3plputas2rixzWhDFia-agw1e2f8DdLtx_xzpgQSM778h44D0LPCJQEmHi5LgmrScEIVyVRSpRCAAFKaXl7D83O2n00g1wtKmD0IXqU0hqACCbIBbqQnFLF5Qz9no8b04fBxe_B4sWwCsswhXHAo8eNmZxdjd2djr84G92d5OPY42aVd-N9GHDjui69wlc_Q-sG6_C0MtPfUYuEP7g25LQWL3d4zrAZWjzn-NQbf3bWbaYxpsfogTddck-O5yX69vbqa_OuuPl0vWje3BSWMaAFrQwBwa3N43BWeMV9ToCla4G3layINFBLlodDGCiQlktfMStaKiXI2laX6MUhdxPHH1uXJt2HZPM_zODGbdJ1rSiTTP3TSGqglVI0G18fjDaOKUXn9SaG3sSdJqD32PRa79HoPRq9x6ZP2PRtvv302Ga77F17vnvklPXnR90kazofzWBDOtuoEpTXJNuuD7ZfoXO7_3mBfv-xyetUqP4AKPG1KA</recordid><startdate>199601</startdate><enddate>199601</enddate><creator>Dahmer, Mary K.</creator><creator>Senogles, Susan E.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>199601</creationdate><title>Dopaminergic Inhibition of Catecholamine Secretion from Chromaffin Cells: Evidence that Inhibition Is Mediated by D4 and D5 Dopamine Receptors</title><author>Dahmer, Mary K. ; Senogles, Susan E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4402-23a1065cc046ec6f95fece0bed05d38318a0784199140908c58f34c6d288087c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - pharmacology</topic><topic>Adenylate Cyclase Toxin</topic><topic>Adenylyl cyclase</topic><topic>Adenylyl Cyclases - metabolism</topic><topic>Adrenal gland</topic><topic>Adrenal Medulla - drug effects</topic><topic>Adrenal Medulla - metabolism</topic><topic>Adrenals. Interrenals</topic><topic>Adrenomedullary hormones. Regulation</topic><topic>Animals</topic><topic>Base Sequence</topic><topic>Benzazepines - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Bromocriptine - pharmacology</topic><topic>Ca2+ uptake</topic><topic>Calcium - physiology</topic><topic>Catecholamines - metabolism</topic><topic>Cattle</topic><topic>Cells, Cultured</topic><topic>Colforsin - pharmacology</topic><topic>Cyclic AMP - physiology</topic><topic>Depression, Chemical</topic><topic>Dimethylphenylpiperazinium Iodide - antagonists &amp; inhibitors</topic><topic>Dopamine - physiology</topic><topic>Dopamine Agonists - pharmacology</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Molecular Sequence Data</topic><topic>PCR</topic><topic>Pertussis Toxin</topic><topic>Polymerase Chain Reaction</topic><topic>Potassium - antagonists &amp; inhibitors</topic><topic>Receptors, Dopamine - drug effects</topic><topic>Receptors, Dopamine - genetics</topic><topic>Receptors, Dopamine - physiology</topic><topic>Receptors, Dopamine D1 - physiology</topic><topic>Receptors, Dopamine D2 - physiology</topic><topic>Receptors, Dopamine D4</topic><topic>Receptors, Dopamine D5</topic><topic>Second Messenger Systems - drug effects</topic><topic>Veratridine - antagonists &amp; inhibitors</topic><topic>Vertebrates: endocrinology</topic><topic>Virulence Factors, Bordetella - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dahmer, Mary K.</creatorcontrib><creatorcontrib>Senogles, Susan E.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neurochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dahmer, Mary K.</au><au>Senogles, Susan E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dopaminergic Inhibition of Catecholamine Secretion from Chromaffin Cells: Evidence that Inhibition Is Mediated by D4 and D5 Dopamine Receptors</atitle><jtitle>Journal of neurochemistry</jtitle><addtitle>J Neurochem</addtitle><date>1996-01</date><risdate>1996</risdate><volume>66</volume><issue>1</issue><spage>222</spage><epage>232</epage><pages>222-232</pages><issn>0022-3042</issn><eissn>1471-4159</eissn><coden>JONRA9</coden><abstract>: Previous studies have suggested that activation of D2‐like dopamine receptors inhibits catecholamine secretion from adrenal chromaffin cells. The purpose of this study was to determine whether the activation of D1‐like receptors on chromaffin cells affects either catecholamine release from the cells or the inhibition of secretion by D2‐like dopamine receptors. Both D1‐ and D2‐selective agonists inhibited secretion elicited by dimethylphenylpiperazinium (DMPP), veratridine, and high K+ levels. The D1‐selective agonists 6‐chloro‐7,8‐dihydroxy‐3‐allyl‐1‐phenyl‐2,3,4,5‐tetrahydro‐1H‐3‐benzazepine (Cl‐APB) and SKF‐38393 inhibited DMPP‐stimulated catecholamine secretion in a concentration‐dependent manner; 50% inhibition was obtained with ∼10 µM Cl‐APB and ∼100 µM SKF‐38393. Of the D2‐selective agonists, bromocriptine was a more potent inhibitor of DMPP‐stimulated catecholamine release than was quinpirole. The inhibition of secretion caused by Cl‐APB or SKF‐38393 was additive with the inhibition caused by bromocriptine. Pertussis toxin treatment (50 ng/ml, 18 h) attenuated the inhibitory effect of D2‐selective, but not D1‐selective, dopamine agonists. In addition, forskolin‐stimulated adenylyl cyclase activity was inhibited by D2‐selective, but not D1‐selective, agonists. Neither D1‐ nor D2‐selective agonists stimulated adenylyl cyclase activity in the cells, although cyclase activity was stimulated by forskolin, carbachol, and vasoactive intestinal peptide. DMPP‐stimulated Ca2+ uptake was inhibited by both D1‐ and D2‐selective dopamine agonists. PCR analysis was used to determine which of the dopamine receptor subtypes within the D1‐like and D2‐like subfamilies was responsible for the observed inhibition. PCR analysis indicated that mRNA for only D4 and D5 dopamine receptor subtypes was present in chromaffin cells. These combined data suggest that D1‐ and D2‐selective agonists inhibit Ca2+ uptake and catecholamine secretion by activating D4 and D5 dopamine receptors on chromaffin cells.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>8522958</pmid><doi>10.1046/j.1471-4159.1996.66010222.x</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3042
ispartof Journal of neurochemistry, 1996-01, Vol.66 (1), p.222-232
issn 0022-3042
1471-4159
language eng
recordid cdi_proquest_miscellaneous_77924849
source MEDLINE; Wiley Journals
subjects 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - pharmacology
Adenylate Cyclase Toxin
Adenylyl cyclase
Adenylyl Cyclases - metabolism
Adrenal gland
Adrenal Medulla - drug effects
Adrenal Medulla - metabolism
Adrenals. Interrenals
Adrenomedullary hormones. Regulation
Animals
Base Sequence
Benzazepines - pharmacology
Biological and medical sciences
Bromocriptine - pharmacology
Ca2+ uptake
Calcium - physiology
Catecholamines - metabolism
Cattle
Cells, Cultured
Colforsin - pharmacology
Cyclic AMP - physiology
Depression, Chemical
Dimethylphenylpiperazinium Iodide - antagonists & inhibitors
Dopamine - physiology
Dopamine Agonists - pharmacology
Fundamental and applied biological sciences. Psychology
Molecular Sequence Data
PCR
Pertussis Toxin
Polymerase Chain Reaction
Potassium - antagonists & inhibitors
Receptors, Dopamine - drug effects
Receptors, Dopamine - genetics
Receptors, Dopamine - physiology
Receptors, Dopamine D1 - physiology
Receptors, Dopamine D2 - physiology
Receptors, Dopamine D4
Receptors, Dopamine D5
Second Messenger Systems - drug effects
Veratridine - antagonists & inhibitors
Vertebrates: endocrinology
Virulence Factors, Bordetella - pharmacology
title Dopaminergic Inhibition of Catecholamine Secretion from Chromaffin Cells: Evidence that Inhibition Is Mediated by D4 and D5 Dopamine Receptors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T08%3A26%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dopaminergic%20Inhibition%20of%20Catecholamine%20Secretion%20from%20Chromaffin%20Cells:%20Evidence%20that%20Inhibition%20Is%20Mediated%20by%20D4%20and%20D5%20Dopamine%20Receptors&rft.jtitle=Journal%20of%20neurochemistry&rft.au=Dahmer,%20Mary%20K.&rft.date=1996-01&rft.volume=66&rft.issue=1&rft.spage=222&rft.epage=232&rft.pages=222-232&rft.issn=0022-3042&rft.eissn=1471-4159&rft.coden=JONRA9&rft_id=info:doi/10.1046/j.1471-4159.1996.66010222.x&rft_dat=%3Cproquest_cross%3E17023992%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17023992&rft_id=info:pmid/8522958&rfr_iscdi=true